GNI Group Ltd.
We Bring New Hope to Life 2026 Fiscal Year Q3 Earnings Presentation
With the consolidation of Ayumi Pharmaceutical and progress in the F351 NDA application, the company is entering a growth phase toward becoming a global biopharma. Revenue for July–September increased 53.6% year-over-year; acquisition-related expenses for Ayumi Pharmaceutical temporarily raised costs. Full-year revenue forecast remains unchanged at 47,327 hundred million yen. F351 is under priority review with NDA submission progress, acceptance of the NDA, completion of on-site inspection, and potential commercialization at the end of 2026 or Q1 2027.
Key Figures
- Revenue: 29,731 hundred million yen (Cumulative Q3 2026)
- Operating Income: 73 million yen
- Full-year Revenue Forecast: 47,327 hundred million yen
AI要約
Performance Overview
Cumulative revenue for Q3 of fiscal 2026 was 29,731 hundred million yen, a significant increase year-over-year. Consolidation of Ayumi Pharmaceutical and acquisition-related expenses for Cullgen increased one-off costs. Meanwhile, Gyre's clinical activities and preparations for the NDA submission for F351 are progressing, building a new growth foundation aimed at becoming a global biopharma. Full-year revenue remains unchanged at 47,327 hundred million yen.
Outlook and Risks
The NDA for F351 has been accepted and on-site inspection completed. Approval could be received by the end of 2026 or in Q1 2027. Consolidation of Ayumi Pharmaceutical is expected to drive profitability in the Japanese market and accelerate global expansion. However, increased R&D and clinical development costs, foreign exchange impact, and M&A-related expenses remain risks to monitor.
Revenue Trend
Margin Analysis
Forecast vs Actual Comparison
GNI Group Ltd.
Company overview · Stock price · Financial data · All IR
